Evotec Secures $2.9 Million Gates Foundation Grant for Drug Safety Testing

By Public Technologies
  • Evotec secured a $2.9 million grant from the Gates Foundation to extend early drug safety testing for three years.
  • The project, launched in 2023, uses human stem cells to assess potential fetal development risks from drug candidates.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2434956_en) on November 16, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk